

Carmen Mora-Fernández

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7933039/publications.pdf>

Version: 2024-02-01

72
papers

4,940
citations

172457
29
h-index

102487
66
g-index

73
all docs

73
docs citations

73
times ranked

5999
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nature Reviews Nephrology, 2011, 7, 327-340.	9.6	845
2	The Role of Inflammatory Cytokines in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2008, 19, 433-442.	6.1	754
3	Effect of Pentoxifylline on Renal Function and Urinary Albumin Excretion in Patients with Diabetic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 220-229.	6.1	432
4	Inflammatory Cytokines in Diabetic Nephropathy. Journal of Diabetes Research, 2015, 2015, 1-9.	2.3	202
5	Renal Pro-Inflammatory Cytokine Gene Expression in Diabetic Nephropathy: Effect of Angiotensin-Converting Enzyme Inhibition and Pentoxifylline Administration. American Journal of Nephrology, 2006, 26, 562-570.	3.1	192
6	The role of TNF- α in diabetic nephropathy: Pathogenic and therapeutic implications. Cytokine and Growth Factor Reviews, 2006, 17, 441-450.	7.2	173
7	Inflammation in Diabetic Kidney Disease. Nephron, 2019, 143, 12-16.	1.8	164
8	Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clinical Science, 2009, 116, 479-492.	4.3	160
9	Diabetic kidney disease: from physiology to therapeutics. Journal of Physiology, 2014, 592, 3997-4012.	2.9	142
10	<i>Reviews</i>: Clinical Implications of Disordered Magnesium Homeostasis in Chronic Renal Failure and Dialysis. Seminars in Dialysis, 2009, 22, 37-44.	1.3	136
11	Reduced Klotho is associated with the presence and severity of coronary artery disease. Heart, 2014, 100, 34-40.	2.9	129
12	Urinary tumour necrosis factor- α excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrology Dialysis Transplantation, 2006, 21, 3428-3434.	0.7	114
13	Inflammatory Targets in Diabetic Nephropathy. Journal of Clinical Medicine, 2020, 9, 458.	2.4	109
14	Expression of FGF23/KLOTHO system in human vascular tissue. International Journal of Cardiology, 2013, 165, 179-183.	1.7	89
15	Mineral Metabolism and Inflammation in Chronic Kidney Disease Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1646-1654.	4.5	83
16	Effect of Phosphate Binders on Serum Inflammatory Profile, Soluble CD14, and Endotoxin Levels in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2272-2279.	4.5	82
17	Tumor necrosis factor- α as a therapeutic target for diabetic nephropathy. Cytokine and Growth Factor Reviews, 2009, 20, 165-173.	7.2	71
18	Amino acid losses during hemodialysis with polyacrylonitrile membranes: effect of intradialytic amino acid supplementation on plasma amino acid concentrations and nutritional variables in nondiabetic patients. American Journal of Clinical Nutrition, 2000, 71, 765-773.	4.7	66

#	ARTICLE	IF	CITATIONS
19	Serum Magnesium Concentration is An Independent Predictor of Parathyroid Hormone Levels in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 1999, 19, 455-461.	2.3	61
20	Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease. <i>Diabetes Care</i> , 2018, 41, 1817-1820.	8.6	60
21	Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor- α and interleukin-6 in type 2 diabetic patients. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 919-926.	0.7	54
22	Pentoxifylline for Renoprotection in Diabetic Nephropathy: the PREDIAN study. Rationale and basal results. <i>Journal of Diabetes and Its Complications</i> , 2011, 25, 314-319.	2.3	48
23	Implications of Klotho in vascular health and disease. <i>World Journal of Cardiology</i> , 2014, 6, 1262.	1.5	45
24	Association of tumor necrosis factor- α with early target organ damage in newly diagnosed patients with essential hypertension. <i>Journal of Hypertension</i> , 2008, 26, 2168-2175.	0.5	40
25	Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. <i>Journal of Clinical Medicine</i> , 2019, 8, 287.	2.4	40
26	Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications. <i>Frontiers in Medicine</i> , 2020, 7, 628289.	2.6	39
27	FGF23/Klotho axis: Phosphorus, mineral metabolism and beyond. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 37-46.	7.2	37
28	Soluble levels and endogenous vascular gene expression of <i>KLOTHO</i> are related to inflammation in human atherosclerotic disease. <i>Clinical Science</i> , 2017, 131, 2601-2609.	4.3	37
29	Association between serum levels of Klotho and inflammatory cytokines in cardiovascular disease: a case-control study. <i>Aging</i> , 2020, 12, 1952-1964.	3.1	35
30	Influence of Klotho gene polymorphisms on vascular gene expression and its relationship to cardiovascular disease. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 128-133.	3.6	32
31	Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. <i>Cytokine and Growth Factor Reviews</i> , 2016, 28, 71-77.	7.2	29
32	Anti-inflammatory Profile of Paricalcitol in Hemodialysis Patients: A Prospective, Open-label, Pilot Study. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 421-426.	2.0	27
33	Klotho in cardiovascular disease: Current and future perspectives. <i>World Journal of Biological Chemistry</i> , 2015, 6, 351.	4.3	27
34	Serum and Gene Expression Profile of Tumor Necrosis Factor- α and Interleukin-6 in Hypertensive Diabetic Patients: Effect of Amlodipine Administration. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 51-59.	2.1	25
35	Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy. <i>Diabetes Care</i> , 1999, 22, 1006-1008.	8.6	23
36	Fibroblast growth factor 23 expression in human calcified vascular tissues. <i>Aging</i> , 2019, 11, 7899-7913.	3.1	23

#	ARTICLE	IF	CITATIONS
37	Relationship between inflammation and microalbuminuria in prehypertension. <i>Journal of Human Hypertension</i> , 2013, 27, 119-125.	2.2	22
38	Klotho expression in peripheral blood circulating cells is associated with vascular and systemic inflammation in atherosclerotic vascular disease. <i>Scientific Reports</i> , 2022, 12, 8422.	3.3	22
39	Effects of Atorvastatin on Lipid Profile and Non-Traditional Cardiovascular Risk Factors in Diabetic Patients on Hemodialysis. <i>Nephron Clinical Practice</i> , 2003, 95, c128-c135.	2.3	21
40	Serum urate is related to subclinical inflammation in asymptomatic hyperuricaemia. <i>Rheumatology</i> , 2021, 60, 371-379.	1.9	21
41	Effect of different membranes on amino-acid losses during haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 113-117.	0.7	19
42	Pathophysiological Implications of Fibroblast Growth Factor-23 and Klotho and Their Potential Role as Clinical Biomarkers. <i>Clinical Chemistry</i> , 2014, 60, 933-940.	3.2	19
43	Erdheim-Chester disease as cause of end-stage renal failure: a case report and review of the literature. <i>International Urology and Nephrology</i> , 2010, 42, 1107-1112.	1.4	18
44	Effect of Androgens on Anemia and Malnutrition in Renal Failure: Implications for Patients on Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2001, 21, 1-15.	2.3	17
45	Klotho as a biomarker of subclinical atherosclerosis in patients with moderate to severe chronic kidney disease. <i>Scientific Reports</i> , 2021, 11, 15877.	3.3	17
46	Hypermagnesemia in Capd. Relationship with Parathyroid Hormone Levels. <i>Peritoneal Dialysis International</i> , 1998, 18, 77-79.	2.3	16
47	Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients. <i>Transplantation</i> , 2016, 100, 2432-2438.	1.0	16
48	Inflammatory Pathways. <i>Contributions To Nephrology</i> , 2011, 170, 113-123.	1.1	15
49	FGF23 and Klotho Levels are Independently Associated with Diabetic Foot Syndrome in Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2019, 8, 448.	2.4	15
50	Pathophysiological Implications of Imbalances in Fibroblast Growth Factor 23 in the Development of Diabetes. <i>Journal of Clinical Medicine</i> , 2021, 10, 2583.	2.4	9
51	Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 1997, 13, 257-9.	0.1	8
52	Errors in the Selection of Dialysate Concentrates Cause Severe Metabolic Acidosis During Bicarbonate Hemodialysis. <i>Artificial Organs</i> , 2008, 21, 966-968.	1.9	7
53	Androgens for the treatment of anemia in peritoneal dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 1998, 14, 232-5.	0.1	7
54	Effect of Nandrolone Decanoate on the Lipid Profile of Male Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2001, 21, 611-614.	2.3	6

#	ARTICLE	IF	CITATIONS
55	Beneficial Effects of Selective Vitamin D Receptor Activation by Paricalcitol in Chronic Kidney Disease. <i>Current Drug Targets</i> , 2014, 15, 703-709.	2.1	6
56	Negative Effect of Angiotensin-Converting Enzyme Inhibitors on Erythropoietin Response in CAPD Patients. <i>American Journal of Nephrology</i> , 2000, 20, 248-248.	3.1	5
57	Relationship between serum parathyroid hormone levels and lipid profile in hemodialysis patients. Evolution of lipid parameters after parathyroidectomy. <i>Clinical Nephrology</i> , 1998, 49, 303-7.	0.7	5
58	Effect of Angiotensin-Converting Enzyme Inhibitors on Hematological Parameters and Recombinant Human Erythropoietin Doses in Peritoneal Dialysis Patients. <i>Nephron</i> , 1998, 80, 239-239.	1.8	4
59	Perfil antiinflamatorio del paricalcitol en el receptor de trasplante renal. <i>Nefrologia</i> , 2017, 37, 622-629.	0.4	4
60	Magnesium in Chronic Renal Failure. , 2007, , 303-315.		4
61	Hemodialysis Urea Rebound and Membrane Biocompatibility: Accuracy of Kt/V Estimations. <i>Artificial Organs</i> , 1997, 21, 91-95.	1.9	3
62	Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2200-2213.	2.9	3
63	Serum Amino Acids in Dialysis Patients: The Tryptophan/Serotonin Disorder Hypothesis and Implications for Uremic Anorexia. <i>Peritoneal Dialysis International</i> , 2001, 21, 625-626.	2.3	1
64	Lanthanum Carbonate Modulates Inflammatory Profile in Hemodialysis Patients: Relationship with Fibroblast Growth Factor-23. <i>European Journal of Inflammation</i> , 2013, 11, 75-86.	0.5	1
65	Anti-inflammatory profile of paricalcitol in kidney transplant recipients. <i>Nefrologia</i> , 2017, 37, 622-629.	0.4	1
66	Electronic Patient-Reported Outcomes in Nephrology: Focus on Hemodialysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 861.	2.4	1
67	Acute renal failure associated with foscarnet therapy. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 221-221.	0.7	0
68	Intradialytic Amino Acid Supplementation. <i>Nephron</i> , 2002, 90, 509-509.	1.8	0
69	MO440KLOTHO AS A BIOMARKER OF SUBCLINICAL CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A PROOF-OF-CONCEPT STUDY*. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
70	MO037EPIGENETIC REGULATION OF KLOTHO IN PERIPHERAL BLOOD CIRCULATING CELLS IS ASSOCIATED WITH SOLUBLE PROTEIN SERUM IN CARDIOVASCULAR DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
71	MO031KLOTHO GENE PROMOTER METHYLATION IN THE VASCULATURE IS RELATED TO INFLAMMATION IN HUMAN ATHEROSCLEROSIS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
72	MO453SERUM AND VASCULAR FIBROBLAST GROWTH FACTOR 23 (FGF23) ARE ASSOCIATED WITH VASCULAR CALCIFICATION. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0